Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3849891 · 1 trial · 2 indications
A summary of TEAEs and AEs, regardless of causality, will be reported in the Reported Adverse Events module
PD: Mean change from baseline on liver inflammation and fibrosis content measured by MRI
| Arm | Type | Description |
|---|---|---|
| LY3849891 (Part A) | EXPERIMENTAL | Single ascending doses of LY3849891 administered subcutaneously (SC) |
| LY3849891 (Part B) | EXPERIMENTAL | Repeated doses of LY3849891 administered SC |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY3849891 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Participants must have a body mass index (BMI) within the range greater than or equal to (≥) 25 and less than (\<) 50 kilogram per square meter (kg/m²) inclusive * Participants must have liver fat content ≥10% in Part A and ≥8% for Part B as determined by MRI-PDFF * Participan...
LY3849891 is an investigational small molecule developed by Eli Lilly and Company for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease. It is in Phase 1 clinical development and has been studied in a single completed trial. It is not an approved medicine.
LY3849891 is being developed to treat metabolic dysfunction-associated steatohepatitis (MASH), also referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). The Phase 1 program enrolled participants with these liver conditions rather than healthy volunteers, and the study has been completed.
LY3849891 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 clinical study of the compound in participants with metabolic dysfunction-associated steatotic liver disease.
LY3849891 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. Because it remains investigational, LY3849891 has not been approved by the FDA for any indication.
LY3849891 has been evaluated in one Phase 1 trial, NCT05395481, titled a single-ascending and repeated dose study in participants with metabolic dysfunction-associated steatotic liver disease. The trial enrolled 115 participants across the United States, Japan, and Puerto Rico and is now completed.
The Phase 1 trial NCT05395481 was a randomized, double-blind, placebo-controlled study of single-ascending and repeated doses of LY3849891 in adults with metabolic dysfunction-associated steatotic liver disease. It enrolled 115 participants aged 18 years and older, including both sexes, and used a biomarker-selected population.